https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/qualifying-notice-elrexfio-273519.html
Qualifying notice for Elrexfio (273519) - Canada.ca
A Notice of Compliance with Conditions (NOC/c) is authorization to market a drug (i.e. a Notice of Compliance (NOC)), with the condition that the Sponsor...
qualifyingnoticeelrexfiocanada
https://elrexfiorems.com/
ELREXFIO REMS | elranatamab-bcmm
The purpose of the ELREXFIO REMS is to mitigate the risks of cytokine release syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated...
elrexfioremselranatamabbcmm
https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-elrexfio
Drug Trials Snapshots: ELREXFIO | FDA
ELREXFIO is a drug used to treat a form of blood cancer called multiple myeloma.
drug trials snapshotselrexfiofda